BLASTID, Inc.
Developer of a benchtop, culture-free diagnostic platform that isolates and characterizes live pathogens directly from whole blood using microfluidics, label-free high-resolution imaging, and AI-driven image analysis. The platform is designed to deliver species identification and phenotypic antibiotic susceptibility results within hours from a standard clinical blood draw. The company is a Harvard spinout and is engaged in clinical and translational collaborations and ARPA-H-funded programs; its platform is under development and not FDA approved.
Industries
Nr. of Employees
small (1-50)
Products
Benchtop culture-free direct-from-blood diagnostic platform
A compact instrument and single-use cartridge workflow that isolates live pathogens from whole blood, performs label-free high-resolution imaging, and applies AI-driven analysis to deliver species ID and phenotypic AST within hours.
Benchtop culture-free direct-from-blood diagnostic platform
A compact instrument and single-use cartridge workflow that isolates live pathogens from whole blood, performs label-free high-resolution imaging, and applies AI-driven analysis to deliver species ID and phenotypic AST within hours.
Services
Partnerships with hospital systems, clinical laboratories, and stakeholders for validation, clinical studies, and integration of culture-free direct-from-blood diagnostics into routine practice.
Testing and demonstration of direct-from-blood isolation outputs integrated with downstream automated phenotypic AST instruments.
Partnerships with hospital systems, clinical laboratories, and stakeholders for validation, clinical studies, and integration of culture-free direct-from-blood diagnostics into routine practice.
Testing and demonstration of direct-from-blood isolation outputs integrated with downstream automated phenotypic AST instruments.
Expertise Areas
- Direct-from-blood diagnostics
- Phenotypic antibiotic susceptibility testing
- Microfluidic pathogen enrichment
- Label-free live-cell microscopy
Key Technologies
- Microfluidics
- Differential phase / super-resolution microscopy
- AI / machine-learning image analysis
- Single-cell phenotypic assays
News & Updates
Poster demonstration of ultra-rapid isolation of pathogens from blood samples and compatibility with an FDA-approved automated AST system (presentation at ADLM 2025, Chicago).
Press release describing proof-of-concept direct-from-whole-blood organism isolation, enrichment, and phenotypic AST with reported ability to deliver AST results (MIC values) in less than 8 hours from blood draw.
Publication (Nature Communications) by collaborators describing a mechanistic AI framework for antimicrobial peptide design and single-cell assays used to evaluate activity against S. aureus persisters and biofilms.
Summary of ARPA-H Defeating Antibiotic Resistance through Transformative Solutions (DARTS) award (up to $104M) led by academic collaborators; describes development of microscopy, microfluidics, single-cell assays, and ML tools for rapid diagnostics and antibiotic discovery.
Demonstrated technical feasibility to isolate and enrich organisms directly from whole blood and run rapid phenotypic AST on an external automated AST instrument, reporting MIC values in under 8 hours.
Poster demonstration of ultra-rapid isolation of pathogens from blood samples and compatibility with an FDA-approved automated AST system (presentation at ADLM 2025, Chicago).
Press release describing proof-of-concept direct-from-whole-blood organism isolation, enrichment, and phenotypic AST with reported ability to deliver AST results (MIC values) in less than 8 hours from blood draw.
Publication (Nature Communications) by collaborators describing a mechanistic AI framework for antimicrobial peptide design and single-cell assays used to evaluate activity against S. aureus persisters and biofilms.
Summary of ARPA-H Defeating Antibiotic Resistance through Transformative Solutions (DARTS) award (up to $104M) led by academic collaborators; describes development of microscopy, microfluidics, single-cell assays, and ML tools for rapid diagnostics and antibiotic discovery.
Demonstrated technical feasibility to isolate and enrich organisms directly from whole blood and run rapid phenotypic AST on an external automated AST instrument, reporting MIC values in under 8 hours.